<DOC>
<DOCNO>
EP-0004394
</DOCNO>
<TEXT>
<DATE>
19791003
</DATE>
<IPC-CLASSIFICATIONS>
C07K-1/113 A61P-25/00 C07K-14/435 C07K-14/655 C07K-1/00 C07K-14/675 C07K-14/575 A61P-25/20 <main>C07C-103/52</main> A61K-37/02 C07K-14/67 A61K-38/00 
</IPC-CLASSIFICATIONS>
<TITLE>
psychopharmacological peptides, process for their preparation and their pharmaceutical formulations.
</TITLE>
<APPLICANT>
akzo nvnl<sep>akzo n.v.<sep>akzo n.v.velperweg 76nl-6824 bm arnhemnl<sep>akzo n.v.<sep>
</APPLICANT>
<INVENTOR>
de wied david prof dr<sep>greven hendrik marie<sep>de wied, david, prof. dr.<sep>greven, hendrik marie<sep>de wied, david, prof. dr.lassuslaan 41bilthovennl<sep>greven, hendrik mariedeken van der cammenweg 13heeschnl<sep>de wied, david, prof. dr.  <sep>greven, hendrik marie <sep>de wied, david, prof. dr.lassuslaan 41bilthovennl<sep>greven, hendrik mariedeken van der cammenweg 13heeschnl<sep>
</INVENTOR>
<ABSTRACT>
novel and biologically useful peptides of the formula:  a₁-a₂-l-phe-x-l-thr-l-ser-r₁-y-l-ser-r₂-l-thr-l-­ pro-l-leu-l-val-l-thr-b are disclosed (together with  pharmaceutical compositions comprising a pharmaceutically  effective amount of same) wherein:   (a) a₁ and a₂ each represent an aminoacid residue of the  formula h₂n-alk-co-, where alk is an alkylidene  group with 1 to 6 carbon atoms inclusively;   (b) x is an amino-acid residue selected from the group  consisting of l-met, l-met(o), l-met(o₂) and l-leu;   (c) r₁ and r₂ each represent one of the amino-acid residues  selected from the group consisting of l-glu and  l-gln;   (d) y represents an amino acid residue selected from the  group consisting of l-lys and d-lys; and   (e) b represents one of the amino-acid or peptide moieties  selected from l-leu-oh, d-leu-oh,  l-leu-l-phe-oh, l-leu-l-phe-l-lys-oh,  l-leu-l-phe-d-lys-oh, l-leucinol and  l-meleu-oh.    or a functional derivative thereof; these peptides have psychopharmacological  properties capable of accelerating the  inhibition of the conditioned flight response, so that they  are eminently suitable for the treatment of certain mental  disorders in which reduction of the brain function is desired;  more particularly the peptides have neuroleptic activity.   peptides of formula (i) wherein one of r₁ and r₂ is l-glu  and the other l-gln are preferred, and compositions containing  compositions of formula (i) wherein r₁ is l-glu and  r₂ is l-gln are especially suitable.  
</ABSTRACT>
</TEXT>
</DOC>
